A single-arm, phase II study of niraparib and bevacizumab maintenance in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor (KGOG 3056/NIRVANA-R)

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Internal Medicine

Show all topics

DOI

10.3802/jgo.2024.35.s2.pi-so2